Drug Profile
PAT 505
Alternative Names: PAT-505Latest Information Update: 28 Nov 2020
Price :
$50
*
At a glance
- Originator PharmAkea Therapeutics
- Class Small molecules
- Mechanism of Action ENPP2 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hepatic fibrosis; Non-alcoholic steatohepatitis
Most Recent Events
- 28 Nov 2020 No recent reports of development identified for preclinical development in Hepatic-fibrosis in USA (PO)
- 28 Nov 2020 No recent reports of development identified for preclinical development in Non-alcoholic-steatohepatitis in USA (PO)
- 17 Oct 2016 Preclinical trials in Hepatic fibrosis and Non-alcoholic steatohepatitis in USA (PO), before October 2016